Tuesday 27 October 2026 Export LLY’s income statement to Excel — free account

Eli Lilly and Company

LLY Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.

1,285.05 5.91 +0.46%

Follow LLY

Alert me

Market cap: $1.20T
P/E: 42.9×
Fwd P/E: 36.7×
Dividend yield: 0.52%
F-score: 7/9
Altman Z: 8.61
Beneish M: −1.91
Dividend safety: 86/100

Overview Business Profile Earnings & Analysis Segments Filings

Eli Lilly and Company (LLY) revenue by segment, product and region

	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024	Q4 FY2023	Q3 FY2023	Q2 FY2023	Q1 FY2023
Reportable Segment	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Animal Health Products	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Endocrinology	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Neuroscience	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Oncology	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Cardiovascular	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other Pharmaceuticals	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Eliminations	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Human Pharmaceutical Products	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

Eli Lilly and Company (LLY) revenue by segment, product and region

Stockrow Weekly